CSIR Features in the Thomson Reuters Top 50 Indian Innovator Companies and Research Organizations for the Year 2015

Image result for Council of Scientific and Industrial Research (CSIR)

CSIR Features in the Thomson Reuters Top 50 Indian Innovator Companies and Research Organizations for the Year 2015

The Council of Scientific and Industrial Research (CSIR) features in the Thomson Reuters top 50 Indian Innovator companies and research organizations for the year 2015. The Top 50 Indian Innovators lead the country in innovation output. They are a group of businesses and research institutions that develop, recognize and protect great ideas and use it to their full potential.

Thomson Reuters India Innovation Awards honors the most innovative academic institutions and commercial enterprises headquartered in India for their spirit of innovation in R&D as it relates to Indian patent publications. Thomson Reuters 2015 India Innovation Awards is based on research and analysis done using the Derwent World Patents Index, the world’s most trusted and authoritative value-added patent database. Data from 2010-2014 was used for the analysis. The metrics used are patent volume, grant success rate, globalization, and citation influence. This analysis is done using proprietary Thomson Reuters data and tools. The threshold for inclusion in the Top 50 Indian innovators is at least 25 patents published during the period 2010-2014.

Six innovators from the top 50 list have also been selected as the recipients of the Thomson Reuters India Innovation Awards 2015 across three different industrial sectors: Corporate-Pharmaceuticals, Corporate-Hi Tech., and Academic & Research Institutions.

CSIR was also the recipient of the Thomson Reuters India Innovation Awards 2013 in the category of Hi-Tech Academic & Government.

CSIR, constituted in 1942 by a resolution of the then Central Legislative assembly, is an autonomous body registered under the Registration of Societies Act XXI of 1860. Known for its cutting-edge R&D knowledgebase in diverse S&T areas, CSIR is a contemporary R&D organization, having pan-India presence, with a dynamic network of 38 national laboratories, 39 outreach centers, 3 Innovation Complexes and 5 units.

CSIR covers a wide spectrum of science and technology – from radio and space physics, oceanography, geophysics, chemicals, drugs, genomics, biotechnology and nanotechnology to mining, aeronautics, instrumentation, environmental engineering and information technology. It provides significant technological intervention in many areas with regard to societal efforts, which include environment, health, drinking water, food, housing, energy, farm and non-farm sectors. Further, CSIR’s role in S&T human resource development is noteworthy.

Pioneer of India’s intellectual property movement, CSIR today is strengthening its patent portfolio to carve out global niches for the country in select technology domains. CSIR is granted 90% of US patents granted to any Indian publicly funded R&D organization. On an average CSIR files about 200 Indian patents and 250 foreign patents per year. About 9% of CSIR patents are licensed - a number which is above the global average. Amongst its peers in publicly funded research organizations in the world, CSIR is a leader in terms of filing and securing patents worldwide.

The next challenge that the Institution places before itself is to convert this wealth of innovation for societal and industrial outcomes much beyond the present. 


Partnering to Explore New Possibilities in Diabetes Research

The Minister of State for Science & Technology and Earth Sciences, Shri Y.S. Chowdary, presided over the Memorandum of Agreement (MoA) signing ceremony between the Drug Discovery Research Centre (DDRC) and Revelations Biotech Pvt. Ltd. (RBPL), a Hyderabad based Research and Development Company. DDRC is a niche Centre of the Translational Health Science and Technology Institute (THSTI) Faridabad, of the Department of Biotechnology, Government of India. The research collaboration will focus on developing new approaches for diagnosis and treatment of Diabetes.

The Minister said that sadly India stands out as the diabetic capital of the world and the continuing increase in incidence of this disease is a cause of serious concern. Diabetes is a gateway to a host of other diseases and hence needs to be checked on its very onset. He further said that if we spend Rs.100 for the prevention of a disease then we save around Rs.400 which would otherwise be spent on the curation process. He gave a motto ‘Illness to Wellness’ for this drive to find a preventive measure to pre-empt and prevent Diabetes at very early stages. Shri Chowdary also laid stress on the importance of Translational Research which leads to translation of cutting edge research works by scientists in their labs to manufacturing low cost drugs for the masses, with the contribution from the private sector.

The annual expenditure for Diabetes treatment in India is to the tune of Rs. 1.5 lakh crores. Diabetes is a chronic progressive metabolic disorder that is characterized by chronic hyperglycemia with disturbances of carbohydrate, fat, and protein metabolism. Although previously thought to represent a problem of middle-agebut recently there has been a rapid rise in incidence of Diabetes in the youth as well. This is largely due to lifestyle changes where a high calorie diet is coupled with sedentary habits. Hence there is an urgent need for more sensitive methods for detection and for more effective regimens for treatment.

Prof. K. VijayRaghavan, Secretary, Department of Bio-technology, speaking at the occasion said that the DDRC-RBPL collaboration will focus on addressing these needs through two separate programs. Firstly, to develop a data based software package that will not only identify individuals who are becoming susceptible to diabetes but also predict the future course of disease in those who are already diabetic. It is hoped that the advance warning provided by such a system will allow the target individuals to pre-emptively make appropriate lifestyle alterations so as to mitigate the disease onset and prevent its progression. The second program is to develop a new drug that will prevent re-absorption of glucose in the kidneys. This re-absorption process contributes to maintain high glycemic levels in diabetics. Inhibition of this process by an effective drug therefore will lead to a significant lowering of blood glucose levels.

No comments

Powered by Blogger.